In the UK, the Department of Health is the “parent,” or sponsoring department, for the Medicines and Healthcare Products Regulatory Agency (MHRA). That seems reasonable. It would be surprising if […]
Jim Murray
Jim Murray: Undermining the European Medicines Agency’s transparency policy
As previously mentioned, the European Medicines Agency pulled back on its transparency policy when it published a new draft for consultation in May this year. The European Ombudsman and Glenis Willmott […]
Jim Murray: A surprising development in the case of InterMune vs the EMA
InterMune has withdrawn part of its legal challenge to stop the European Medicines Agency from disclosing certain documents, which relate to the medicine Esbriet (Pirfenidone). The company is still looking for […]
Jim Murray: Policy making behind closed doors
Campaigning for transparency on clinical trial results at EU level is getting to be like playing snakes and ladders, and I’ve just spotted three snakes. I’ve been trying to “deconstruct” […]
Jim Murray: Volte-face by the European Medicines Agency?
The European Medicines Agency (EMA) has recently published to a targeted audience final consultation draft papers on its new “proactive” transparency policy on clinical trial results. As reported, information published under […]
Jim Murray: Who cares about the European Parliament?
Many people across Europe regard the European Parliament as irrelevant, or worse. Personally I find this sad but they are entitled to their view. I wrote a blog here a […]
Jim Murray: Abbvie withdraw case against European Medicines Agency
AbbVie have withdrawn their legal challenge against the release of certain company documents on Humira (adalimunab) by the EMA. This followed an offer by the agency to redact parts of […]
Jim Murray: Some MEPs work very hard
I sometimes feel sorry for MEPs, and not just at Christmas. I’m thinking of those who do a good job as rapporteur on important dossiers, such as the revision of […]
Jim Murray: New fronts in the struggle for transparency
The European Court of Justice has struck down and ordered a rehearing of the cases for an interim injunction to stop the European Medicines Agency’s new transparency policy on clinical […]
Jim Murray: Transparency may help to reduce the misselling of medicines
Greater transparency on clinical trial results would help reduce off-label promotion—the promotion of medicines for uses for which they have not been approved. Looking at the US since 2004, I […]